SOURCE: PuriCore Plc

April 18, 2007 08:00 ET

PuriCore Plc announces Director/PDMR Shareholding

Pennsylvania -- (MARKET WIRE) -- April 18, 2007 --18 April 2007

                               Directors' Dealings

                PuriCore Directors Acquire Shares in the Company

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 18 April 2007-PuriCore (LSE: PURI), the life sciences company focused on the development and commercialisation of its novel, safe antimicrobial technology, today announces that the following Directors have purchased shares in the Company, as set out below:

Name           Number of   Purchase
                  shares   Price of   Total number of   % of issued share 
               purchased     shares       shares held             capital

Alan Suggett      35,000        60p            35,000                0.02
Jim Walsh         60,000        52p            60,000                0.04

Contacts:

PuriCore plc                                            +1 (484) 321 2700
Greg Bosch, Chief Executive Officer
Keith A. Goldan, Chief Financial Officer

Financial Dynamics                                   +44 (0) 20 7831 3113
Ben Brewerton
John Gilbert

About PuriCore

PuriCore (London Stock Exchange: PURI) is a life sciences company focused on developing and commercializing proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety, medical device disinfection, wound management, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypocholous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of M. tuberculosis, MRSA, E.coli, norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.

To receive additional information on PuriCore, please visit our web site at www.puricore.com, which does not form part of this press release.

                      This information is provided by RNS
            The company news service from the London Stock Exchange